Lipid discovery, polymer design, drug product development and business development — years of experience across academia and industry, brought under one roof in 2023.
Chief Scientific Officer, Co-Founder
Former researcher at Cornell University and the University of Washington, and holds a Ph.D. from Wuhan University. A polymer chemistry and physics specialist by training with over twenty years of experience, his work underpins the architecture of the CybernaX lipid platform.
Chief Business Officer, CMC Lead
Formerly a Principal Scientist in Pfizer Vaccine R&D and Sterile Drug Product Lead at Frontage Laboratories, and a co-op researcher at GSK. He holds a Ph.D. from Temple University and has more than ten years of research experience in non-viral delivery, spanning formulation development, sterile drug product and CMC.
Lipid Chemistry Lead
Ph.D. from the Leibniz Institute for Catalysis, University of Rostock, Germany, followed by postdoctoral research at the Chinese Academy of Sciences. He specializes in synthetic organic chemistry, with a research background that extends into biochemistry.
Advisor, Academic Co-Founder
Associate Professor at the University of Toronto, where he holds the Canada Research Chair in RNA Vaccines and Therapeutics and the GSK Chair in Pharmaceutics and Drug Delivery. He completed postdoctoral training at MIT and his Ph.D. training at the University of Washington. He is a recipient of the Terry Fox New Investigator Award and the Gairdner Early Career Investigator Award.
Tell us your target tissue, payload and mechanism of action. We will tell you which lipid chemistry gets you there.
info@cybernaxbio.com